TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± Trastuzumab

Breast Cancer Research and Treatment

Volumn 132, Issue 3, 2012, Pages 781-791

  Glück, Stefan ^a   Ross, Jeffrey S ^b   Royce, Melanie ^c   McKenna Jr , Edward F ^d   Perou, Charles M ^e   Avisar, Eli ^a   Wu, Lin ^f  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b ALBANY MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

^d HOFFMANN LA ROCHE INC   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f Roche Molecular Diagnostics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN P53; TRASTUZUMAB; TUMOR MARKER; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; HER2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TAXOID; TP53 PROTEIN, HUMAN;

ADULT; ADVERSE OUTCOME; AGED; ALOPECIA; ANEMIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER INVASION; CANCER STAGING; CLINICAL ASSESSMENT; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE MARKER; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DYSGEUSIA; DYSPEPSIA; DYSPNEA; EARLY CANCER; FATIGUE; FEMALE; GENE EXPRESSION PROFILING; GENETIC VARIABILITY; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INSOMNIA; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MUCOSAL DISEASE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NAIL DISEASE; NAUSEA; NEUTROPENIA; ONCOGENE; OUTCOME ASSESSMENT; PAM50 GENE; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMATITIS; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; VOMITING; ADJUVANT THERAPY; BREAST TUMOR; CLINICAL TRIAL; GENETICS; GENOMICS; LUNG CARCINOMA; METABOLISM; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PAGET NIPPLE DISEASE; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; DEOXYCYTIDINE; DNA MUTATIONAL ANALYSIS; FEMALE; FLUOROURACIL; GENOMICS; HUMANS; MIDDLE AGED; MUTATION; NEOADJUVANT THERAPY; NEOPLASM STAGING; RECEPTOR, ERBB-2; TAXOIDS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84856002018     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1412-7     Document Type: Article

References (43)

1. Mieog JS, Van de Velde CJ (2009) Neoadjuvant chemotherapy for early breast cancer. Expert Opin Pharmacother 10:1423-1434
2. Knauer M, Haid A, Schneider Y, Köberle-Wührer R, Lang A, Winder T, Alton R, Jasarevic Z, Säly C, Offner FA, Wenzl E, de Vries A (2009) Adjuvant extension of chemotherapy after neoadjuvant therapy may not improve outcome in early-stage breast cancer. Eur J Surg Oncol 35:798-804
3. Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS, Paik S, Soran A, Wickerham DL, Wolmark N (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24:2019-2027
4. Heys SD, Hutcheon AW, Sarkar TK, Ogston KN, Miller ID, Payne S, Smith I, Walker LG, Eremin O (2002) Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer 3:S69-S74
5. von Minckwitz G, Blohmer JU, Raab G, Löhr A, Gerber B, Heinrich G, Eidtmann H, Kaufmann M, Hilfrich J, Jackisch C, Zuna I, Costa SD, German Breast Group (2005) In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol 16:56-63
6. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, Ah-See AK, Eremin O, Walker LG, Sarkar TK, Eggleton SP, Ogston KN (2002) Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20:1456-1466
7. von Minckwitz G, Kümmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Huober J, Costa SD, Jackisch C, Loibl S, Mehta K, Kaufmann M, Group German Breast (2008) Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst 100:552-562
8. von Minckwitz G, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Kühn T, du Bois A, Blohmer JU, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, Untch M (2010) Capecitabine in addition to anthracycline-and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol 28:2015-2023
9. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, De Cillis A, Robidoux A, Margolese RG, Cruz AB Jr, Hoehn JL, Lees AW, Dimitrov NV, Bear HD (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685
10. Rouzier R, Mathieu MC, Sideris L, Youmsi E, Rajan R, Garbay JR, André F, Marsiglia H, Spielmann M, Delaloge S (2004) Breast-conserving surgery after neoadjuvant anthracycline-based chemotherapy for large breast tumors. Cancer 101:918-925
11. Mauri D, Pavlidis N, Ioannidis JP (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 97:188-194
12. Jones S, Holmes FA, O'Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ, Pippen JE, Bordelon JH, Kirby RL, Sandbach J, Hyman WJ, Richards DA, Mennel RG, Boehm KA, Meyer WG, Asmar L, Mackey D, Riedel S, Muss H, Savin MA (2009) Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 27:1177-1183
13. Crump M, Tu D, Shepherd L, Levine M, Bramwell V, Pritchard K (2003) Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21:3066-3071
14. Smith RE, Bryant J, De Cillis A, Anderson S, National Surgical Adjuvant Breast and Bowel Project Experience (2003) Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 21:1195-1204
15. Lee KS, Ro J, Nam BH, Lee ES, Kwon Y, Kwon HS, Chung KW, Kang HS, Kim EA, Kim SW, Shin KH, Kim SK (2008) A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer. Breast Cancer Res Treat 109:481-489
16. Luck HJ, Du Bois A, Schrader I et al (2007) Final results of the AGO breast cancer study group MAMMA-3 trial: first-line capecitabine + paclitaxel vs epirubicin + paclitaxel for highrisk metastatic breast cancer. Breast Cancer Res Treat 106:S67
17. Wardley AM, Pivot X, Morales-Vasquez F, Zetina LM, de Fátima Dias Gaui M, Reyes DO, Jassem J, Barton C, Button P, Hersberger V, Torres AA (2010) Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. J Clin Oncol 28:976-983
18. Robert NJ, Dieras V, Glaspy J, Brufsky A, Bondarenko I, Lipatov O, Perez E, Yardley D, Zhou X, Phan S (2009) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 27:15
19. Steger GG, Greil R, Jakesz R, Lang A, Mlineritsch B, Melbinger-Zeinitzer E, Marth C, Samonigg H, Kubista E, Gnant M (2009) A randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer-first results of the Austrian Breast and Colorectal Cancer Study Group-Trial 24 (ABCSG-24). Eur J Cancer Suppl 7: Abstract 4BA
20. Wildiers H, Neven P, Christiaens MR, Squifflet P, Amant F, Weltens C, Smeets A, van Limbergen E, Debrock G, Renard V, Van Eenoo L, Wynendaele W, Paridaens R (2010) Neoadjuvant capecitabine and docetaxel (plus trastuzumab): effective nonanthracycline-based chemotherapy regimen for patients with locally advanced breast cancer. Ann Oncol
21. Olivier M, Langerød A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bièche I, Varley J, Bignon Y, Uhrhammer N, Winqvist R, Jukkola-Vuorinen A, Niederacher D, Kato S, Ishioka C, Hainaut P, Børresen-Dale AL (2006) The clinical value of somatic TP53 gene mutations in 1, 794 patients with breast cancer. Clin Cancer Res 12:1157-1167
22. Norberg T, Lennerstrand J, Inganäs M, Bergh J (1998) Comparison between p53 protein measurements using the luminometric immunoassay and immunohistochemistry with detection of p53 gene mutations using cDNA sequencing in human breast tumors. Int J Cancer 79:376-383
23. Harris LN, Broadwater G, Lin NU, Miron A, Schnitt SJ, Cowan D, Lara J, Bleiweiss I, Berry D, Ellis M, Hayes DF, Winer EP, Dressler L (2006) Molecular subtypes of breast cancer in relation to paclitaxel response, outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res 8:R66
24. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160-1167
25. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10
26. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25:4414-4422
27. Grollman AP, Shibutani S, Moriya M, Miller F, Wu L, Moll U, Suzuki N, Fernandes A, Rosenquist T, Medverec Z, Jakovina K, Brdar B, Slade N, Turesky RJ, Goodenough AK, Rieger R, Vukelić M, Jelaković B (2007) Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci USA 104:12129-12134
28. L'Espérance S, Popa I, Bachvarova M, Plante M, Patten N, Wu L, Têtu B, Bachvarov D (2006) Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors. Int J Oncol 29:5-24
29. Clopper CJ, Pearson ES (1934) The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26:404
30. Steger GG, Galid A, Gnant M, Mlineritsch B, Lang A, Tausch C, Rudas M, Greil R, Wenzel C, Singer CF, Haid A, Pöstlberger S, Samonigg H, Luschin-Ebengreuth G, Kwasny W, Klug E, Kubista E, Menzel C, Jakesz R, ABCSG-14 (2007) Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14. J Clin Oncol 25:2012-2018
31. Han S, Kim J, Lee J, Chang E, Gwak G, Cho H, Yang KH, Park S, Park K (2009) Comparison of 6 cycles versus 4 cycles of neoadjuvant epirubicin plus docetaxel chemotherapy in stages II and III breast cancer. Eur J Surg Oncol 35:583-587
32. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678-5685
33. Baselga J, Semiglazov V, Manikhas GM, et al (2007) Efficacy of neoadjuvant trastuzumab in patients with inflammatory breast cancer: data from the NOAH (NeOAdjuvant Herceptin) phase III trial. Eur J Cancer Suppl 4: Abstract 2030
34. Aas T, Børresen AL, Geisler S, Smith-Sørensen B, Johnsen H, Varhaug JE, Akslen LA, Lønning PE (1996) Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2:811-814
35. Geisler S, Lønning PE, Aas T, Johnsen H, Fluge O, Haugen DF, Lillehaug JR, Akslen LA, Børresen-Dale AL (2001) Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 61:2505-2512
36. Andersson J, Larsson L, Klaar S, Holmberg L, Nilsson J, Inganäs M, Carlsson G, Ohd J, Rudenstam CM, Gustavsson B, Bergh J (2005) Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF. Ann Oncol 16:743-748
37. Di Leo A, Tanner M, Desmedt C, Paesmans M, Cardoso F, Durbecq V, Chan S, Perren T, Aapro M, Sotiriou C, Piccart MJ, Larsimont D, Isola J, AX T, 303 translational study team (2007) p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. Ann Oncol 18:997-1003
38. Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C, Schlagbauer-Wadl H, Mittlböck M, Gnant M, Steger G, Jakesz R (2000) TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 6:50-56
39. Carvajal D, Tovar C, Yang H, Vu BT, Heimbrook DC, Vassilev LT (2005) Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res 65:1918-1924
40. Learn PA, Yeh IT, McNutt M, Chisholm GB, Pollock BH, Rousseau DL Jr, Sharkey FE, Cruz AB, Kahlenberg MS (2005) HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma. Cancer 103:2252-2260
41. Sjöström J, Blomqvist C, Heikkilä P, Boguslawski KV, Räisänen-Sokolowski A, Bengtsson NO, Mjaaland I, Malmström P, Ostenstadt B, Bergh J, Wist E, Valvere V, Saksela E (2000) Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer. Clin Cancer Res 6:3103-3110
42. Hamilton A, Larsimont D, Paridaens R, Drijkoningen M, van de Vijver M, Bruning P, Hanby A, Houston S, Treilleux I, Guastalla JP, Van Vreckem A, Sylvester R, Piccart M (2000) A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923. Clin Breast Cancer 1:233-240
43. Van Poznak C, Tan L, Panageas KS, Arroyo CD, Hudis C, Norton L, Seidman AD (2002) Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer. J Clin Oncol 20:2319-2326